Bayer has added another clinical trial to its extensive phase 3 programme for oral neurokinin antagonist elinzanetant, hoping to show that it can treat vasomotor symptoms (VMS) in breast cancer ...

Bayer AG reported positive results for elinzanetant in women with or at high risk of a type of breast cancer, broadening the use case for the menopause treatment expected to launch as early as ...

Tuesday, Bayer AG (OTC:BAYRY) (OTC:BAYZF) announced topline results of the Phase 3 study OASIS 3 evaluating the efficacy and long-term safety of the investigational compound elinzanetant versus ...

BERLIN--(BUSINESS WIRE)--Bayer today announced positive topline results of the Phase III study OASIS 4 investigating elinzanetant as non-hormonal treatment for moderate to severe vasomotor ...

Elinzanetant meets all primary and secondary endpoints in phase III study OASIS 4 for treatment of moderate to severe vasomotor symptoms caused by breast cancer treatments. News release.

(RTTNews) - Bayer Aktiengesellschaft (BAYRY.PK), Thursday announced that Elinzanetant, a non-hormonal drug, has met all primary and second endpoints in the Phase III study OASIS 4, investigating ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

1. Elinzanetant meets all primary and secondary endpoints in phase 3 study OASIS 4 for treatment of moderate to severe vasomotor symptoms caused by breast cancer treatments. Bayer. News release.

Submissions for marketing authorisations for elinzanetant are ongoing in the US, EU, UK and other markets globally, Bayer outlined.

Bayer only had its filing for approval of the NK-1 and NK-3 antagonist elinzanetant accepted for review in October 2024. Yet, while Bayer is playing catch-up in the menopause space, the German ...

reinforcing Bayer’s leadership in these important therapeutic areas Investigational compound elinzanetant met all primary and secondary endpoints in Phase III study OASIS 4 for the treatment of ...

Although Bayer’s top-selling drug Xarelto lost market exclusivity in most geographies in 2024, the company still predicts it will see strong growth from the pharma business unit beginning in 2027.